Testing cannabidiol for early psychosis
Treatments studied
Part of Mental health clinical trials.
This trial tests whether adding cannabidiol (CBD) to clozapine improves symptoms in people with early psychosis. It is for those who have been on clozapine for at least 8 weeks and still have some symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 50 years old.
- You have been taking clozapine for at least 8 weeks and have a certain level of the medicine in your blood.
- You started taking antipsychotic medicine for psychosis within the last 10 years.
- You have a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- You still have some symptoms like delusions, disorganized thinking, or lack of emotion despite treatment.
- If you can become pregnant, you must use highly effective birth control during and 3 months after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.
This trial tests a specialized cannabis clinic designed to help people cut back or stop using cannabis if they've had a first episode of psychosis. The goal is to see if the clinic helps reduce cannabis use and improve mental health.
This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.
This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.
This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.
This trial tests whether cannabidiol (CBD) can reduce symptoms of bipolar depression. You may be eligible if you have bipolar I or II and a current depressive episode while staying on approved mood-stabilizing or antipsychotic medication.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.